Opinion|Videos|November 27, 2024
Emerging Horizons in HER2-Directed NSCLC Treatments
Key Takeaways
- Recent trials, including SOHO-01, inetetamab/pyrotinib, and BEAMION Lung 01, show promising results for HER2-directed therapies in NSCLC.
- Advancements in targeting HER2 mutations suggest potential improvements in treatment efficacy and patient outcomes.
A review of recent clinical trial results for emerging HER2-directed therapies, including SOHO-01, inetetamab/pyrotinib, and BEAMION Lung-01, and their potential impact on the future treatment landscape for HER2-positive NSCLC.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Several HER2-directed therapies are currently in development. Could you discuss the recent clinical trial results for emerging agents, such as those from the SOHO-01, the inetetamab/pyrotinib combination study, and the BEAMION Lung 01 data and what implications might these findings have for the future landscape of HER2-directed therapies in NSCLC?
Advertisement
Related to this article
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Surrogate End Points, Drug Costs Complicate Oncology Formularies
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5